Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer.
Eichenauer T, Hussein M, Hube-Magg C, Kluth M, Büscheck F, Höflmayer D, Tsourlakis MC, Steurer S, Clauditz TS, Luebke AM, Burandt E, Wilczak W, Hinsch A, Dum D, Beyer B, Steuber T, Huland H, Graefen M, Simon R, Sauter G, Melling N, Schlomm T, Minner S. Eichenauer T, et al. Oncotarget. 2019 Mar 1;10(18):1729-1744. doi: 10.18632/oncotarget.26739. eCollection 2019 Mar 1. Oncotarget. 2019. PMID: 30899444 Free PMC article.
Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes.
Büscheck F, Fraune C, Simon R, Kluth M, Hube-Magg C, Möller-Koop C, Sarper I, Ketterer K, Henke T, Eichelberg C, Dahlem R, Wilczak W, Sauter G, Fisch M, Eichenauer T, Rink M. Büscheck F, et al. Among authors: eichenauer t. Oncotarget. 2020 Jan 21;11(3):237-249. doi: 10.18632/oncotarget.27428. eCollection 2020 Jan 21. Oncotarget. 2020. PMID: 32076485 Free PMC article.
High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer.
Eichenauer T, Federlein F, Möller K, Chirico V, Kind S, Lennartz M, Lutz F, Hube-Magg C, Höflmayer D, Fisch M, Huland H, Heinzer H, Graefen M, Haese A, Schroeder C, Lebok P, Minner S, Simon R, Sauter G, Schlomm T, Wilczak W, Steurer S, Luebke AM. Eichenauer T, et al. Pathology. 2020 Jun;52(4):421-430. doi: 10.1016/j.pathol.2020.03.001. Epub 2020 Apr 18. Pathology. 2020. PMID: 32317175
Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
Bernreuther C, Daghigh F, Möller K, Hube-Magg C, Lennartz M, Lutz F, Rico SD, Fraune C, Dum D, Luebke AM, Eichenauer T, Möller-Koop C, Schlomm T, Wittmer C, Huland H, Heinzer H, Graefen M, Haese A, Burandt E, Tsourlakis MC, Clauditz TS, Höflmayer D, Izbicki JR, Simon R, Sauter G, Minner S, Steurer S, Meiners J. Bernreuther C, et al. Among authors: eichenauer t. Pathol Oncol Res. 2020 Oct;26(4):2709-2722. doi: 10.1007/s12253-020-00861-9. Epub 2020 Jul 16. Pathol Oncol Res. 2020. PMID: 32677026 Free PMC article.
βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.
Hinsch A, Chaker A, Burdelski C, Koop C, Tsourlakis MC, Steurer S, Rink M, Eichenauer TS, Wilczak W, Wittmer C, Fisch M, Simon R, Sauter G, Büschek F, Clauditz T, Minner S, Jacobsen F. Hinsch A, et al. Among authors: eichenauer ts. Hum Pathol. 2017 Mar;61:210-220. doi: 10.1016/j.humpath.2016.11.005. Epub 2016 Dec 24. Hum Pathol. 2017. PMID: 28025079
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, Grupp K, Eichenauer T, Becker A, Adam M, Graefen M, Huland H, Kurtz S, Steurer S, Tsourlakis MC, Minner S, Michl U, Schlomm T, Sauter G, Simon R, Sirma H. Krohn A, et al. Among authors: eichenauer t. J Pathol. 2013 Sep;231(1):130-41. doi: 10.1002/path.4223. J Pathol. 2013. PMID: 23794398
Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
Büscheck F, Fraune C, Simon R, Kluth M, Hube-Magg C, Möller-Koop C, Shadanpour N, Bannenberg C, Eichelberg C, Höflmayer D, Clauditz T, Wittmer C, Wilczak W, Sauter G, Fisch M, Rink M, Eichenauer T. Büscheck F, et al. Among authors: eichenauer t. Urol Oncol. 2018 Dec;36(12):531.e19-531.e25. doi: 10.1016/j.urolonc.2018.08.015. Epub 2018 Oct 12. Urol Oncol. 2018. PMID: 30322727
Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer.
Kind S, Büscheck F, Höflmayer D, Hube-Magg C, Kluth M, Tsourlakis MC, Steurer S, Clauditz TS, Luebke AM, Burandt E, Wilczak W, Hinsch A, Dum D, Weidemann S, Fraune C, Beyer B, Steuber T, Huland H, Graefen M, Fisch M, Simon R, Sauter G, Schlomm T, Minner S, Eichenauer T. Kind S, et al. Among authors: eichenauer t. World J Urol. 2020 Sep;38(9):2185-2196. doi: 10.1007/s00345-019-03017-w. Epub 2019 Nov 19. World J Urol. 2020. PMID: 31745645
8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival.
Eichenauer T, Bannenberg DC, Kluth M, Wittmer C, Büscheck F, Möller K, Dum D, Fraune C, Hube-Magg C, Möller-Koop C, Dahlem R, Fisch M, Rink M, Riechardt S, Tsourlakis MC, Bernreuther C, Minner S, Simon R, Sauter G, Wilczak W, Clauditz TS. Eichenauer T, et al. Urol Oncol. 2020 Feb;38(2):43.e13-43.e20. doi: 10.1016/j.urolonc.2019.09.024. Epub 2019 Nov 19. Urol Oncol. 2020. PMID: 31757738 Free article.
Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer.
Eichenauer T, Simmendinger L, Kluth M, Chirico V, Luebke AM, Höflmayer D, Hinsch A, Jacobsen F, Hube-Magg C, Möller-Koop C, Dahlem R, Fisch M, Rink M, Riechardt S, Tsourlakis MC, Büscheck F, Bernreuther C, Clauditz T, Lebok P, Simon R, Sauter G, Wilczak W, Fraune C. Eichenauer T, et al. Urol Oncol. 2020 Jun;38(6):605.e1-605.e8. doi: 10.1016/j.urolonc.2020.02.022. Epub 2020 Mar 30. Urol Oncol. 2020. PMID: 32241691
23 results